Tier 1 — highest

Effects of Vitamin D3 and Marine Omega-3 Fatty Acids Supplementation on Biomarkers of Systemic Inflammation: 4-Year Findings from the VITAL Randomized Trial

Yanbin Dong, Haidong Zhu, Li Chen, Ying Huang, William Christen, Nancy R Cook, Trisha Copeland, Samia Mora, Julie E Buring, I-Min Lee, Karen H Costenbader, JoAnn E Manson
Nutrients 2022 14(24):5307

Bibliography

PubMed
PMID 36558465
PubMed Central
PMC9782648
DOI
10.3390/nu14245307
Trial registry
View on ClinicalTrials.gov Registered trial — results not yet published in a peer-reviewed journal.
Funding
Support is recorded from NCI NIH HHS, NIAMS NIH HHS, NHLBI NIH HHS, NCCIH NIH HHS. See the original publication for grant and material-support details.
Competing interests
The authors report no relevant competing interests.

Study snapshot

DesignInflammatory-biomarker substudy of the randomized VITAL trial
ModelHuman participants
Sample1,054 participants; 2,713 blood samples
InterventionVitamin D3 2,000 IU/day and/or omega-3 1 g/day
DurationMeasurements at baseline, 2 and 4 years
Endpointshs-CRP; IL-6; IL-10; TNF-α

What the study showed, in plain terms

This publication examines hs-crp, il-6, il-10, tnf-α. Study population or evidence base: 1,054 participants; 2,713 blood samples. Intervention or exposure: Vitamin D3 2,000 IU/day and/or omega-3 1 g/day.

Key findings

Vitamin D reduced hs-CRP at year two, but the effect was not significant at year four. Other measured inflammatory markers were not significantly improved.

What this study can and cannot tell us

A biomarker substudy with time-dependent findings. It does not demonstrate sustained generalized anti-inflammatory effects or clinical disease prevention.

Related papers in the corpus

Tier 1
Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease
JoAnn E Manson et al. · The New England journal of medicine · 2019
Tier 1
Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults
Meryl S LeBoff et al. · The New England journal of medicine · 2022
Tier 1
Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial
Jill Hahn et al. · BMJ (Clinical research ed.) · 2022
Tier 1
Vitamin D and Marine n-3 Fatty Acids for Autoimmune Disease Prevention: Outcomes Two Years After Completion of a Double-Blind, Placebo-Controlled Trial
Karen H Costenbader et al. · Arthritis & rheumatology (Hoboken, N.J.) · 2024
Tier 1
Effect of Long-term Vitamin D3 Supplementation vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial
Olivia I Okereke et al. · JAMA · 2020
Tier 1
Vitamin D supplementation vs. placebo and incident type 2 diabetes in an ancillary study of the randomized Vitamin D and Omega-3 Trial
Deirdre K Tobias et al. · Nature communications · 2025

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Biohack Blueprint Research